FOR IMMEDIATE RELEASE

MAJOR ADVANCEMENT FOR WAFERMINE® AS US GOVERNMENT OPENS EMERGENCY USE PATHWAY FOR MILITARY ACUTE PAIN



- **Wafermine® reaches the final regulatory step.**
  With four milestones completed, only FDA grant of EUA remains pending.

Singapore, 7 September 2026 — iX Biopharma Ltd (**iX Biopharma** or the **Company**) is pleased to announce a major US regulatory development for Wafermine®, its sublingual ketamine wafer for moderate-to-severe acute pain. The US Government has opened an emergency use pathway for drugs to treat moderate-to-severe acute pain in military casualties, clearing the way for the Company to advance its Wafermine® Emergency Use Authorization (**EUA**) submission to the FDA.

On 3 September 2026, the US Government published the Emergency Use Authorization Declaration (**Declaration**). It follows the US Secretary of War's determination, under section 564(b)(1)(B) of the US Federal Food, Drug, and Cosmetic Act, that a military emergency, or a significant potential for one, exists involving a heightened risk of attack on US forces.

Injuries from such attacks may cause moderate-to-severe acute pain and place personnel at risk of life-threatening haemodynamic instability, including shock or respiratory distress. On that basis, the Secretary of Health and Human Services declared, under section 564, that circumstances exist justifying the emergency use of drugs identified and supported by the Department of War (DOW) to address that need.

Major advancement for Wafermine®

In February 2026, iX Biopharma received a sole-source US$41 million award to develop Wafermine® for the treatment of moderate-to-severe acute pain, including funding the activities required to pursue an FDA EUA for military use and the Company's Phase 3 clinical programme (**Award**). Sole-source awards are made when DOW determines that only one source can meet its requirement.

The Declaration confirms that circumstances exist for the FDA to consider Wafermine® for EUA. Before the Declaration, supply of Wafermine® to US military personnel would have required full FDA approval. With the statutory precondition under section 564 now satisfied, a regulatory route exists, subject to the FDA granting an EUA.

Together, the DOW Award and the Declaration bring the funding, development programme and regulatory pathway into alignment, materially advancing and de-risking Wafermine®.

Declarations under this military pathway are extremely rare. Based on publicly available US Federal Register records, the only previous declaration was made in July 2018, in respect of freeze-dried plasma for the treatment of uncontrolled haemorrhage in combat casualties.

Next step: Wafermine® EUA submission

With the support of the DOW, iX Biopharma will continue advancing its Wafermine® EUA submission to the FDA. Work on the filing is already under way, and the Company anticipates completing the submission by 4Q 2026.

If granted, an EUA would allow Wafermine® to be deployed for authorised use by US military personnel before full FDA approval. This creates the potential for Wafermine® to begin generating revenue ahead of full FDA approval and in parallel with the Company's ongoing Phase 3 programme.

Mr Eddy Lee, Chairman and CEO of iX Biopharma, said, "No company can bring about a declaration of this kind; it requires the US Government to act, and declarations under this pathway are extremely rare. That the US Government has taken this step validates what we have said about this programme throughout – Wafermine is being developed within a US government-supported programme addressing a critical unmet medical need. Our focus now is completing the EUA submission and getting Wafermine to US military personnel urgently."

The Declaration is available at:
https://www.federalregister.gov/documents/2026/09/03/2026-18008/emergency-use-authorization-declaration

About iX Biopharma Ltd.

iX Biopharma (SGX: 42C) is a specialty pharmaceutical company with expertise in novel drug delivery systems and drug repurposing. Its proprietary WaferiX and WaferlogiX platform enables rapid, effective sublingual dosing for pharmaceuticals and nutraceuticals. The Group develops, manufactures and commercialises innovative therapies for the treatment of acute and breakthrough pain and other health conditions.

Forward-Looking Statements

This release contains forward-looking statements, including statements about the anticipated completion of the Company's EUA submission, the FDA's review, and the potential grant of an Emergency Use Authorization for Wafermine®, as well as the timing and outcome of the Company's Phase 3 programme. These statements are based on current expectations and are subject to risks and uncertainties, including that the FDA may not grant an EUA, may grant one later than anticipated, may impose conditions or require additional information, and may subsequently amend, suspend or revoke any EUA granted, and that clinical and regulatory timelines may change. Actual results may differ materially from those expressed or implied. iX Biopharma undertakes no obligation to update these statements except as required by law.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Alex Tan
8PR
T: +65 9451 5252
E: alex.tan@8prasia.com